CHEWTADZY

Growth

tadalafil

NDAORALTABLET, CHEWABLE
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of…

Indications (4)

erectile dysfunction (ED)the signssymptoms of benign prostatic hyperplasia (BPH)symptoms of BPH (ED/BPH)

Clinical Trials (5)

NCT06805513Phase 3Recruiting

Actual Use Trial of Tadalafil 5 mg

Started Jan 2025
2,250 enrolled
Erectile Dysfunction
NCT04540744Phase 1Completed

A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil

Started Apr 2021
18 enrolled
Healthy
NCT04235270Phase 1Completed

A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants

Started Jan 2020
62 enrolled
Healthy
NCT04069936Phase 2Terminated

Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC

Started Oct 2019
19 enrolled
Non Small Cell Lung CancerLung CancerLung Cancer Metastatic+5 more
NCT03309592Phase 4Withdrawn

Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension

Started Oct 2017
0
Portopulmonary HypertensionPulmonary HypertensionCirrhosis, Liver
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers